Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...
That's Gazyva in SLE, [indiscernible], the fenebrutinib data in PPMS. For several Phase II assets ... percentage of uveitis patients will develop uveitic macular edema at some point in their uveitis ...
Graph Neural Networks for Anomaly Detection in Cloud Infrastructure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback